Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

التفاصيل البيبلوغرافية
العنوان:	Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
المؤلفون:	Ramgopal, Moti N, Castagna, Antonella, Cazanave, Charles, Diaz-Brito, Vicens, Dretler, Robin, Oka, Shinichi, Osiyemi, Olayemi, Walmsley, Sharon, Sims, James, Di Perri, Giovanni, Sutton, Kenneth, Sutherland-Phillips, Denise, Berni, Alessandro, Latham, Christine L, Zhang, Feifan, D'Amico, Ronald, Pascual Bernáldez, Miguel, Van Solingen-Ristea, Rodica, Van Eygen, Veerle, Patel, Parul, Chounta, Vasiliki, Spreen, William R, Garges, Harmony P, Smith, Kimberly, van Wyk, Jean ^*
المصدر:	In The Lancet HIV September 2023 10(9):e566-e577
قاعدة البيانات:	ScienceDirect

الوصف
تدمد:	23523018
DOI:	10.1016/S2352-3018(23)00136-4